Logo

Becton Dickinson: Joanne Waldstreicher

Jul 28, 2023

Becton Dickinson has named Joanne Waldstreicher to its board of directors. Waldstreicher most recently served as Chief Medical Officer for Johnson & Johnson where she was responsible for safety, epidemiology, regulatory, and clinical operations transformations, as well as bioethics and late-stage pipeline program review from 2012 until her retirement in 2023. She previously held positions at Janssen Pharmaceutical Research and Development and Merck Research Laboratories.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.